Overview
XFOR market data
Price History
XFOR price chart · 1M
- O
- 4.15
- H
- 4.39
- L
- 4.15
- C
- 4.23
- Vol
- 40,389.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $4.15
- Previous Close
- $4.17
- Day High
- $4.39
- Day Low
- $4.15
- 52 Week High
- $4.82
- 52 Week Low
- $3.56
- 7 Day Return
- +4.84%
- 30 Day Return
- +7.51%
- 90 Day Return
- -1.86%
- 1 Year Return
- +3.05%
- Daily Notional Volume
- $170.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.87 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.43 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,106.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.80 – $4.83 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $404.6M · P/B 1.96 · P/S 44.89.
Company News
FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat CongenitalBenzinga · Aug 26, 2026, 4:54 PM
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga · Aug 10, 2026, 12:02 PM
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 7, 2026, 4:04 PM
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M EstimateBenzinga · Aug 6, 2026, 9:22 PM
Wells Fargo Initiates Coverage On X4 Pharmaceuticals with Overweight Rating, Announces Price Target of $11Benzinga · Jul 10, 2026, 12:25 PM
8-K filing — X4 Pharmaceuticals, Inc (XFOR)SEC EDGAR · Jul 1, 2026, 8:13 PM
Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12Benzinga · Jun 2, 2026, 1:20 PM